Using Site-Specific Chemical Conjugation to Generate Superior Half-Life Extended or PD1-Targeted Formats of a Potent IL-18 Variant Resistant to IL-18 Binding Protein

News

Using Site-Specific Chemical Conjugation to Generate Superior Half-Life Extended or PD1-Targeted Formats of a Potent IL-18 Variant Resistant to IL-18 Binding Protein

Bright Peak Therapeutics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Learn more about our privacy policies here.